Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergic Rhinitis AND Allergy AND Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    141 result(s) found for: Allergic Rhinitis AND Allergy AND Asthma. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2007-003058-26 Sponsor Protocol Number: ModAll-Der/07 Start Date*: 2007-07-17
    Sponsor Name:LOFARMA
    Full Title: Pilot study on tolerability of specific immunotherapywith injective allergoid adsorbed on calcium phosphate in patients with respiratory allergy to house dust mite.
    Medical condition: allergic rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000754-19 Sponsor Protocol Number: AL1602av Start Date*: 2017-11-09
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid...
    Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001029-84 Sponsor Protocol Number: AL0702rB Start Date*: 2007-08-30
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised, placebo-controlled, double-blind pivotal clinical trial for the evaluation of safety and efficacy of specific of immunotherapy with an aluminium hydroxide-adsorbed hypoall...
    Medical condition: ICD classification code: J45.0 and J30.1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-005400-28 Sponsor Protocol Number: AL1502AV Start Date*: 2016-06-20
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhin...
    Medical condition: Patients with seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma during the birch pollen season
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004920-12 Sponsor Protocol Number: PRO-2013 Start Date*: 2014-02-12
    Sponsor Name:LETI Pharma GmbH
    Full Title: Non-interventional Study in Allergic Patients Suffering from Grass Pollen Induced Rhinitis/Rhinoconjunctivitis with or without Asthma. Retrospective Assessment of the Efficacy of a Perennial Speci...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis with or without concomitant asthma due to grass pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    14.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-002409-13 Sponsor Protocol Number: AL1501AV Start Date*: 2015-11-19
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter, randomized, open-label clinical trial to evaluate safety and tolerability of a year-round initiation of specific immunotherapy with an aluminum hydroxide adsorbed allergoid preparati...
    Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10039776 Seasonal allergic rhinitis LLT
    19.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    19.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    19.0 100000004855 10001705 Allergic asthma LLT
    19.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006099-12 Sponsor Protocol Number: TSO-01 Start Date*: 2007-12-21
    Sponsor Name:Statens Serum Institut
    Full Title: Oral treatment of allergy with a non-pathogenic microorganism: A randomised clinical trial
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006258-16 Sponsor Protocol Number: AL0801rB Start Date*: 2008-11-19
    Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG
    Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant ...
    Medical condition: ICD classification code: J45.0 and J30.1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002808-18 Sponsor Protocol Number: AL0701rP Start Date*: 2007-10-31
    Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG
    Full Title: A double-blind placebo controlled dose-response study for evaluation of safety and efficacy of immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)...
    Medical condition: ICD classification code: J45.0 and J30.1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000548-25 Sponsor Protocol Number: AL1605av Start Date*: 2018-06-18
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid...
    Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10001705 Allergic asthma LLT
    21.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002277-38 Sponsor Protocol Number: MT-06 Start Date*: 2011-10-06
    Sponsor Name:ALK-Abelló A/S
    Full Title: A one-year trial evaluating the efficacy and safety of the ALK house dust mite allergy immunotherapy tablet in adult subjects with house dust mite allergic rhinitis
    Medical condition: allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10034382 Perennial allergic rhinitis LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001724 Allergic rhinitis (excl hay fever) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) LV (Completed) DK (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002881-42 Sponsor Protocol Number: SL-351A Start Date*: 2023-02-07
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergy
    Medical condition: Patients with grass pollen-related allergic rhinitis/rhino-conjunctivitis (with well-controlled mild-to-moderate or without asthma)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001728-20 Sponsor Protocol Number: AV-X-02 Start Date*: 2013-11-13
    Sponsor Name:ALK-Abelló S. A.
    Full Title: An open trial to assess the tolerability of AVANZ® Salsola immunotherapy
    Medical condition: Allergic rhinoconjunctivitis with or without asthma due to sensitisation to Salsola kali pollen
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004852-20 Sponsor Protocol Number: AV-X-01 Start Date*: 2012-04-10
    Sponsor Name:ALK-Abelló, S.A.
    Full Title: An open trial to assess the tolerability of AVANZ Olive immunotherapy
    Medical condition: Allergic rhinoconjunctivitis with/without asthma due to sensitization to Olea europaea (olive) pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000548-29 Sponsor Protocol Number: ADA103575 Start Date*: 2007-05-04
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg OD versus Mont...
    Medical condition: Persistent asthma and seasonal allergic rhinitis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: EE (Completed) FI (Prematurely Ended) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-003715-22 Sponsor Protocol Number: DMV01-SIT-015 Start Date*: 2020-11-04
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, randomized, placebo-controlled, multi-center trial comparing the efficacy and safety of subcutaneous immunotherapy with a mixture of grasses and mites at adequate doses versus monother...
    Medical condition: Mild to moderate asthma and allergic rhinitis / rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001324-19 Sponsor Protocol Number: BDS_18_01 Start Date*: 2018-08-02
    Sponsor Name:Marinomed Biotech AG
    Full Title: Demonstration of therapeutic equivalence/non-inferiority as well as early onset of action of the novel water-soluble budesonide nasal spray (Budesolv) compared with marketed Rhinocort® aqua 64 in p...
    Medical condition: Allergic Rhinitis/ Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10021428 - Immune system disorders 10019170 Hay fever LLT
    20.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002319-27 Sponsor Protocol Number: SL-61A Start Date*: 2021-02-01
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Birch pollen-related allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018562-23 Sponsor Protocol Number: 6078-PG-PSC-169 Start Date*: 2010-09-15
    Sponsor Name:LETI Pharma GmbH
    Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivi...
    Medical condition: Allergic rhinitis and/or allergic rhinoconjunctivitis with or without intermittent asthma.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) BG (Ongoing) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002296-42 Sponsor Protocol Number: SC-21A Start Date*: 2020-01-31
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 06:32:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA